Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Cognitive impairment in schizophrenia: aetiology, pathophysiology, and treatment
Cognitive deficits are a core feature of schizophrenia, account for much of the impaired
functioning associated with the disorder and are not responsive to existing treatments. In this …
functioning associated with the disorder and are not responsive to existing treatments. In this …
Reinforcement learning in healthcare: A survey
As a subfield of machine learning, reinforcement learning (RL) aims at optimizing decision
making by using interaction samples of an agent with its environment and the potentially …
making by using interaction samples of an agent with its environment and the potentially …
[HTML][HTML] Half a century of research on antipsychotics and schizophrenia: A scientometric study of hotspots, nodes, bursts, and trends
Abstract Changes over 50 years of research on antipsychotics in schizophrenia have
occurred. A scientometric synthesis of such changes over time and a measure of …
occurred. A scientometric synthesis of such changes over time and a measure of …
European Psychiatric Association guidance on assessment of cognitive impairment in schizophrenia
Background Impairment in a wide range of cognitive abilities has been consistently reported
in individuals with schizophrenia. Both neurocognitive and social cognitive deficits are …
in individuals with schizophrenia. Both neurocognitive and social cognitive deficits are …
Cognitive deficits in psychotic disorders: a lifespan perspective
Individuals with disorders that include psychotic symptoms (ie psychotic disorders)
experience broad cognitive impairments in the chronic state, indicating a dimension of …
experience broad cognitive impairments in the chronic state, indicating a dimension of …
Effectiveness of KarXT (xanomeline-trospium) for cognitive impairment in schizophrenia: post hoc analyses from a randomised, double-blind, placebo-controlled …
The muscarinic receptor agonist xanomeline improved cognition in phase 2 trials in
Alzheimer's disease and schizophrenia. We present data on the effect of KarXT (xanomeline …
Alzheimer's disease and schizophrenia. We present data on the effect of KarXT (xanomeline …
Antipsychotics: mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology
Antipsychotic drugs are central to the treatment of schizophrenia and other psychotic
disorders but are ineffective for some patients and associated with side-effects and …
disorders but are ineffective for some patients and associated with side-effects and …
A non–D2-receptor-binding drug for the treatment of schizophrenia
Background An oral compound, SEP-363856, that does not act on dopamine D2 receptors
but has agonist activity at trace amine–associated receptor 1 (TAAR1) and 5 …
but has agonist activity at trace amine–associated receptor 1 (TAAR1) and 5 …
Schizophrenia: overview and treatment options
KR Patel, J Cherian, K Gohil… - Pharmacy and …, 2014 - pmc.ncbi.nlm.nih.gov
Schizophrenia: Overview and Treatment Options - PMC Skip to main content Here's how you
know Official websites use .gov A .gov website belongs to an official government organization …
know Official websites use .gov A .gov website belongs to an official government organization …
Cognitive impairment in psychotic illness: prevalence, profile of impairment, developmental course, and treatment considerations
Despite effective pharmacological treatments for psychotic symptoms (eg, hallucinations,
delusions), functional outcomes for people with psychotic disorders are often disappointing …
delusions), functional outcomes for people with psychotic disorders are often disappointing …